

# Jurjan Aman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/579678/publications.pdf>

Version: 2024-02-01

21  
papers

838  
citations

687363

13  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1582  
citing authors

#	ARTICLE	IF	CITATIONS
1	The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri <sup>®</sup> ) in subjects with acute respiratory distress syndrome induced by COVID-19. <i>Trials</i> , 2022, 23, 158.	1.6	6
2	Long-term clinical outcomes of COVID-19 patients treated with imatinib. <i>Lancet Respiratory Medicine</i> , 2022, 10, e34-e35.	10.7	22
3	Depletion of Arg/Abl2 improves endothelial cell adhesion and prevents vascular leak during inflammation. <i>Angiogenesis</i> , 2021, 24, 677-693.	7.2	19
4	Bosutinib reduces endothelial permeability and organ failure in a rat polytrauma transfusion model. <i>British Journal of Anaesthesia</i> , 2021, 126, 958-966.	3.4	4
5	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	166
6	Application of [18F]FLT <sup>18</sup> F PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers. <i>Pulmonary Circulation</i> , 2021, 11, 1-9.	1.7	1
7	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 957-968.	10.7	83
8	Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID <sup>19</sup> imatinib study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1497-1511.	2.5	8
9	In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	10
10	Bosutinib prevents vascular leakage by reducing focal adhesion turnover and reinforcing junctional integrity. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	20
11	Vanishing vessels abiding pulmonary disease: a role for VEGFR2. <i>European Respiratory Journal</i> , 2020, 55, 2000326.	6.7	3
12	Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?. <i>Thorax</i> , 2019, 74, 317-318.	5.6	1
13	The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 55.	2.4	47
14	Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L453-L466.	2.9	55
15	Why vessels do matter in pulmonary disease. <i>Thorax</i> , 2016, 71, 767-769.	5.6	6
16	Globular adiponectin controls insulin-mediated vasoreactivity in muscle through AMPK <sup>1/2</sup> . <i>Vascular Pharmacology</i> , 2016, 78, 24-35.	2.1	26
17	ROCK2 primes the endothelium for vascular hyperpermeability responses by raising baseline junctional tension. <i>Vascular Pharmacology</i> , 2015, 70, 45-54.	2.1	33
18	Targeting Abl Kinases to Regulate Vascular Leak During Sepsis and Acute Respiratory Distress Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1071-1079.	2.4	64

#	ARTICLE	IF	CITATIONS
19	Reversal of Vascular Leak with Imatinib. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1171-1173.	5.6	27
20	Predictors of pulmonary edema formation during fluid loading in the critically ill with presumed hypovolemia*. Critical Care Medicine, 2012, 40, 793-799.	0.9	46
21	Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib. Circulation, 2012, 126, 2728-2738.	1.6	147